Eli Lilly and Company $LLY Shares Purchased by Marietta Wealth Management LLC

Marietta Wealth Management LLC increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 2.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,503 shares of the company’s stock after purchasing an additional 275 shares during the quarter. Eli Lilly and Company accounts for 1.4% of Marietta Wealth Management LLC’s holdings, making the stock its 24th largest holding. Marietta Wealth Management LLC’s holdings in Eli Lilly and Company were worth $10,526,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also made changes to their positions in the business. Simplicity Wealth LLC boosted its position in shares of Eli Lilly and Company by 125.2% during the 2nd quarter. Simplicity Wealth LLC now owns 12,288 shares of the company’s stock worth $9,580,000 after acquiring an additional 6,832 shares in the last quarter. OLD National Bancorp IN boosted its position in shares of Eli Lilly and Company by 3.0% during the 2nd quarter. OLD National Bancorp IN now owns 628,940 shares of the company’s stock worth $490,278,000 after acquiring an additional 18,365 shares in the last quarter. Carolina Wealth Advisors LLC boosted its position in shares of Eli Lilly and Company by 40.0% during the 2nd quarter. Carolina Wealth Advisors LLC now owns 1,312 shares of the company’s stock worth $1,023,000 after acquiring an additional 375 shares in the last quarter. MBL Wealth LLC boosted its position in shares of Eli Lilly and Company by 3.4% during the 2nd quarter. MBL Wealth LLC now owns 1,611 shares of the company’s stock worth $1,256,000 after acquiring an additional 53 shares in the last quarter. Finally, Wealthcare Capital Partners LLC acquired a new position in shares of Eli Lilly and Company during the 2nd quarter worth about $256,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP Daniel Skovronsky bought 1,000 shares of the stock in a transaction on Tuesday, August 12th. The shares were purchased at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the acquisition, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. This represents a 0.73% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO David A. Ricks bought 1,632 shares of the stock in a transaction on Tuesday, August 12th. The shares were bought at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the acquisition, the chief executive officer owned 546,601 shares in the company, valued at $352,431,926.77. The trade was a 0.30% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired 4,514 shares of company stock worth $2,894,841 in the last quarter. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $840.46 on Friday. The business’s fifty day moving average price is $734.60 and its two-hundred day moving average price is $765.98. The stock has a market cap of $795.47 billion, a PE ratio of 54.93, a price-to-earnings-growth ratio of 1.17 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a one year low of $623.78 and a one year high of $937.00.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to analysts’ expectations of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company’s quarterly revenue was up 37.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Morgan Stanley reduced their target price on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating for the company in a report on Friday. Daiwa Capital Markets downgraded Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 target price for the company. in a research note on Sunday, August 17th. JPMorgan Chase & Co. lowered their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating on the stock in a report on Tuesday, September 16th. Wall Street Zen cut Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 20th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Eli Lilly and Company in a report on Saturday, September 27th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $938.94.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.